Restated Q3 2025 Financials Reveal Larger Losses, Severe Going Concern Risk, and Ineffective Controls
GWLL has more than doubled off its 52-week low of $0.059.
Summary
Goldenwell Biotech filed restated Q3 2025 financials, showing a larger net loss and accumulated deficit, reiterated a severe going concern warning, and disclosed ineffective disclosure controls.
Key Events · Corporate Governance and Compliance · GWLL
-
Financial Restatement Worsens Q3 2025 Results
The restatement for Q3 2025 increased the net loss from $(7,985) to $(27,895) and the accumulated deficit from $(1,407,226) to $(1,456,377). This was primarily due to incorrect revenue recognition and expense timing, following similar restatements for Q1 and Q2 2025.
-
Severe Going Concern Warning Reiterated
The company explicitly stated 'substantial doubt' about its ability to continue as a going concern, citing an accumulated net loss of $1,456,377 and an urgent need for $5 million to fund manufacturing facilities. It warned that 'In the absence of such financing, our business will fail.'
-
Ineffective Disclosure Controls
Management concluded that the company's disclosure controls and procedures were not effective as of March 31, 2025, indicating significant weaknesses in financial reporting oversight.
-
Critical Liquidity Position
As of September 30, 2025, the company had a cash balance of only $45,622 and a total stockholders' deficit of $(143,974). The stated cash runway through December 31, 2025, has already passed.
Analysis · GWLL · Manufacturing
This amended quarterly report restates the company's Q3 2025 financials, revealing a significantly larger net loss and increased accumulated deficit due to accounting errors in revenue recognition and expense timing. This follows previous restatements for Q1 and Q2 2025, indicating systemic financial reporting issues. The company reiterates a severe going concern warning, stating an urgent need for $5 million for manufacturing facilities and explicitly noting that the business will fail without this financing. Management also concluded that disclosure controls and procedures were ineffective, further highlighting significant internal control weaknesses.
At the time of this filing, GWLL was trading at $0.52 on OTC in the Manufacturing sector, with a market capitalization of approximately $51.5M. The 52-week trading range was $0.06 to $10.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.